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, but its impact on mortality was more significant after SAVR. Both trials showed that stroke volume and left ventricular cavity size were further significantly reduced immediately after SAVR, whereas there was no such reduction after TAVR.
Moreover, the patients with severe PPM developed acute kidney injury more frequently after SAVR, but not after TAVR (7). Therefore, the combination of lower stroke volume and higher filling pressure at baseline, further reduction in stroke volume, and the development of renal injury post-operatively may explain the higher perioperative and overall mortality in patients with severe PPM after SAVR.
WHY DOES CORONARY ARTERY BYPASS SURGERY INCREASE MORTALITY WITH PPM?
Concomitant CABG increases the duration of surgery with cardioplegia, which possibly affects the myocardium. It was also shown that the rate of coronary flow reserve is reduced in patients with PPM (10). To understand the additional impact of CABG, it will be necessary to compare post-operative hemodynamics between the patients who undergo SAVR with or without CABG. The meta-analysis data, therefore, suggest that TAVR plus percutaneous coronary intervention may be preferable to SAVR and CABG in patients with severe aortic stenosis and coronary artery disease in whom PPM is anticipated.
PPM AND BODY SIZE
The fact that PPM does not have an impact on mortality in overweight patients (1, 11) infant and adult subjects with body weights ranging from 6 to 93 kg. When BSA was measured in 401 subjects by Gehan and George (13), the DuBois formula overestimated BSA by 15% in w15% of cases.
Therefore, further studies are needed to redefine the indexation of EOA in overweight patients.
PPM IN TAVR VERSUS SAVR
Both the PARTNER and CoreValve randomized trials demonstrated that PPM was less common after TAVR than after SAVR (7, 8) . In both trials, mortality was significantly higher in patients with severe PPM, although the mortality rate was higher in the SAVR group, and the higher mortality after SAVR was more striking for the first 3 months after the intervention (2, 3, 14) . It is possible that less PPM after TAVR was in part responsible for the better 1-to 2-year clinical outcomes after TAVR versus SAVR (2, 3) . Therefore, every effort should be made to avoid or prevent PPM especially in patients with a reduced stroke volume, increased diastolic filling pressure, or coronary artery disease requiring revascularization. Also, these features and factors associated with developing PPM and worse clinical outcome after aortic valve replacement should be considered in choosing SAVR versus TAVR in patients with severe aortic stenosis.
